Statins and angiogenesis in non-cardiovascular diseases

Fatemeh Zahedipour, Alexandra E. Butler, Manfredi Rizzo, Amirhossein Sahebkar

Research output: Contribution to journalReview articlepeer-review

6 Citations (Scopus)


Statins inhibit HMG-CoA reductase by competitively inhibiting the active site of the enzyme, thus preventing cholesterol synthesis and reducing the risk of developing cardiovascular disease. Many pleiotropic effects of statins have been demonstrated that can be either related or unrelated to their cholesterol-lowering ability. Among these effects are their proangiogenic and antiangiogenic properties that could offer new therapeutic applications. In this regard, pro- and anti-angiogenic properties of statins have been shown to be dose dependent. Statins also appear to have a variety of non-cardiovascular angiogenic effects in many diseases, some examples being ocular disease, brain disease, cancer, preeclampsia, diabetes and bone disease, which are discussed in this review using reports from in vitro and in vivo investigations.

Original languageEnglish
Article number103320
JournalDrug Discovery Today
Issue number10
Publication statusPublished - Oct 2022


Dive into the research topics of 'Statins and angiogenesis in non-cardiovascular diseases'. Together they form a unique fingerprint.

Cite this